Abstracts tagged "biomarkers and prognostic factors"

Abstract Number: 2212 • 2017 ACR/ARHP Annual Meeting
A Metabolite of C-Reactive Protein, a Marker of Disease Actvity, Is Prognostic of Radiographic Knee OA
Anne C. Bay-Jensen¹, Asger R. Bihlet², Inger Byrjalsen³, Jeppe Andersen⁴, Yi He⁵, Anne Sofie Siebuhr¹, Christian S. Thudium⁶, Bente J. Riis², Claus Christiansen² and Morten Asser Karsdal¹, ¹Rheumatology, Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Clinical Development, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark, ⁴Clinical Development, Nordic Bioscience, Herlev, Denmark, ⁵Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ⁶Biomarkers and Research, Nordic Bioscience, Herlev, Denmark
Background/Purpose: There are two major needs in clinical DMOAD development: Identifying a population with an active and progressive disease to demonstrate significant improvements by an…
Abstract Number: 3032 • 2016 ACR/ARHP Annual Meeting
Abnormalities in the Biological or Haematological Domain of the Essdai Predict an Increase in Systemic Disease Activity the Year after: 5-Year Data from the Prospective Multicenter Assess Cohort
Jacques-Eric Gottenberg¹, Raphaele Seror², Alain Saraux³, Valerie Devauchelle⁴, Emmanuelle Dernis⁵, Philippe Dieudé⁶, Jean-Jacques Dubost⁷, Anne Laure Fauchais⁸, Vincent Goeb⁹, Claire Larroche¹⁰, Véronique Le-Guern¹¹, Eric Hachulla¹², Pierre Yves Hatron¹³, Jacques Morel¹⁴, Aleth Perdriger¹⁵, Stephanie Rist Bouillon¹⁶, Damien Sène¹⁷, Olivier Vittecoq¹⁸, Jean Sibilia¹⁹, Philippe Ravaud²⁰ and Xavier Mariette²¹, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Department of Rheumatology, Assistance Publique–Hopitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicêtre, France, ³Rheumatology, Brest University Hospital, Brest, France, ⁴Service de Rhumatologie, Department of Rheumatology, Brest University Hospital, Brest, France, Brest, France, ⁵Service de Rhumatologie, Centre Hospitalier, Le Mans, France, ⁶Rheumatology, Hôpital Bichat, Paris, France, ⁷Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁸Rheumatology, Limoges, France, ⁹Rhumatologie, CHU Amiens, Amiens, France, ¹⁰Internal Medicine, Paris, France, ¹¹service de médecine interne, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹²Internal Medicine, Lille University Hospital, Lille, France, ¹³Internal Medicine, Lille, France, ¹⁴Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ¹⁵C.H.R. Hôpital Sud, Rennes, France, ¹⁶Rhumatologie, Hopital La Source, La Source, France, ¹⁷Department of Internal Medicine, Pitié-Salpêtrière Hospital, Paris, France, ¹⁸Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, ¹⁹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²⁰Epidemiologist, PARIS, France, ²¹Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France
Background/Purpose: Very limited data is available regarding predictors of systemic disease activity in primary Sjögren’s syndrome. The ESSDAI, the international systemic disease activity score of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].